NewAmsterdam Pharma Company N.V. (NAMS)

Over the past six months, NewAmsterdam Pharma's stock (NAMS) has trended upwards by 51.76%. In Q3 2025, revenue dropped to $0.35 million, missing expectations, with a net loss of $72.01 million, while Q2 2025 saw GAAP revenue jump to $19.1 million due to a milestone payment. The EMA accepted MAAs for obicetrapib for review, and positive data from the BROADWAY trial was announced and published. Enrollment for the Phase 3 PREVAIL trial was completed in April 2024. Insiders sold 153,647 shares worth $5,484,253. Analysts have given NewAmsterdam Pharma a "Moderate Buy" rating with a price target of $46.73.

As a clinical-stage biopharmaceutical company, NewAmsterdam Pharma Co. NV's revenue is derived from research partnerships and licensing agreements, not direct product sales. Traditional demand seasonality is not applicable to its current business model, as financial performance is tied to clinical milestones and regulatory approvals.

NewAmsterdam Pharma Co. NV (NAMS) is a clinical-stage biopharmaceutical company focused on developing therapies for cardiovascular and metabolic diseases, operating within the Health Technology sector, specifically in the Pharmaceuticals: Major industry. Their primary product candidate is obicetrapib, an oral CETP inhibitor in clinical trials for lowering LDL-C and potentially treating Alzheimer's disease. The company generates revenue through licensing agreements and collaborative research as its therapies await regulatory approval.

NewAmsterdam Pharma Co. NV is headquartered in Naarden, the Netherlands. The company aims to establish a strong global market presence in North America, Europe, and Asia as it advances its drug candidates through clinical trials.

NewAmsterdam Pharma's brand reputation has been positively influenced by its scientific and regulatory advancements, including positive data from the BROADWAY clinical trial, publication of clinical data in the Journal of Prevention of Alzheimer's Disease, and the EMA's acceptance of MAAs for obicetrapib.

NewAmsterdam Pharma Co. NV has significant institutional ownership, with 161 institutional owners holding 121,110,481 shares, approximately 106.34% of the company's stock, while insiders hold about 35.86%. Major institutional owners include Frazier Life Sciences Management, L.P., Bain Capital Life Sciences Investors, LLC, and RA Capital Management, L.P. The largest individual insider shareholder is James N. Topper, who owns 14.63 million shares, representing 12.90% of the company.